We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Unique Metabolic Signature Could Enable Sepsis Diagnosis within One Hour of Blood Collection

By LabMedica International staff writers
Posted on 15 Apr 2024

Sepsis is a life-threatening condition triggered by an extreme response of the body to an infection. More...

It requires immediate medical intervention to prevent potential death or lasting damage. Delay in diagnosing patients with sepsis or septic shock is linked with heightened mortality and morbidity, emphasizing the critical need for prompt diagnosis to improve survival rates. Now, new research findings promise faster diagnosis and better outcomes for sepsis and septic shock patients.

In the study led by Murdoch University (Perth, Australia), researchers successfully used blood plasma metabolic phenotyping to accurately diagnose sepsis or septic shock within an hour of collecting blood samples. This method marks a significant improvement over traditional pathogen culturing techniques, which may take days to yield results. According to the researchers, metabolic signatures were the key to the breakthrough. The study involved the analysis of blood plasma samples collected from 152 patients admitted to the Intensive Care Unit (ICU) within 48 hours—comprising 62 without sepsis, 71 with sepsis, and 19 with septic shock.

The metabolic profiling revealed that patients with sepsis or septic shock displayed higher levels of neopterin and lower levels of HDL cholesterol and phospholipid particles compared to those without sepsis. Septic shock patients could be differentiated from those with only sepsis through different concentrations of 10 specific lipids, including notably reduced levels of five phosphatidylcholine species, three cholesterol esters, one dihydroceramide, and one phosphatidylethanolamine. Utilizing these 15 parameters, which include various metabolites, lipids, lipoproteins, and inflammatory markers, the study achieved high accuracy in accurately classifying patients into their respective clinical outcomes. The research underscores the potential of plasma metabolic phenotyping within 48 hours of ICU admission as a dependable tool for diagnosing sepsis and differentiating between sepsis and septic shock based on lipid profiles.

“As well as impacting individuals and families, sepsis and septic shock pose a significant economic burden to our society,” said Dr. Sam Lodge, from Murdoch University’s Australian National Phenome Centre. “While further validation with a larger cohort is required, this study provides a proof of concept for the potential use of metabolic phenotypes in better diagnosing these conditions.”

Related Links:
Murdoch University


Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Procalcitonin Test
LIAISON B•R•A•H•M•S PCT II GEN
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.